After a review of Portage Biotech Inc. (NasdaqCM:PRTG)'s funding requirements, the Board of Directors has made the decision to pause further drug development in the PORT-2 iNKT program. "This was a difficult decision considering the promising phase 1 safety and translational data from the non-small cell lung and melanoma trial," said Dr. Ian B. Walters, chairman and CEO, "As a result, the company will evaluate a range of potential strategic options which may include among other things, finding a partner for our iNKT program or other corporate transactions".
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2699 USD | +6.98% | -11.71% | -85.17% |
15/04 | Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives | CI |
12/04 | Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-85.17% | 5.34M | |
+26.37% | 48.16B | |
-1.01% | 41.73B | |
+46.00% | 41.03B | |
-5.31% | 28.77B | |
+9.34% | 25.59B | |
-21.69% | 18.96B | |
+6.23% | 12.92B | |
+26.99% | 12.03B | |
-3.38% | 11.77B |
- Stock Market
- Equities
- PRTG Stock
- News Portage Biotech Inc.
- Portage Biotech to Evaluate Range of Strategic Options